Azitra, Inc. (NYSEAMERICAN:AZTR) Shares Shorted: Short Interest Down 65.7% in September

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 240,809 shares, a decline of 65.7% from the September 15th total of 701,345 shares. Based on an average daily volume of 889,711 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.4% of the company’s stock are sold short.

Azitra Stock Down 6.1%

Shares of AZTR traded down $0.01 during midday trading on Monday, reaching $0.12. 257,747 shares of the stock were exchanged, compared to its average volume of 8,211,656. Azitra has a 12-month low of $0.10 and a 12-month high of $1.09. The firm has a 50 day simple moving average of $0.15 and a 200-day simple moving average of $0.18.

Azitra (NYSEAMERICAN:AZTR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). Equities research analysts forecast that Azitra will post -0.20 EPS for the current fiscal year.

About Azitra

Azitra, Inc is a clinical-stage biotechnology company focused on developing live biotherapeutic products for dermatological conditions. The company uses microbiome science and genetic engineering to develop beneficial bacteria designed for topical application to the skin.

Azitra’s research programs have focused on conditions including atopic dermatitis, acne vulgaris and other skin disorders associated with impaired barrier function or microbial imbalance. Its pipeline has included engineered strains of skin-associated bacteria intended to deliver therapeutic proteins or other biological effects directly to affected areas.

The company was founded in 2014 and is based in New Haven, Connecticut.